Obesity may be erythropoietin dose-saving in hemodialysis patients

• Main Authors: Ghada M. El-Kannishy (Author), Abir F. Megahed (Author), Mona M. Tawfik (Author), Ghada El-Said (Author), Rabab T. Zakaria (Author), Nahed A. Mohamed (Author), Eman M. Taha (Author), Alzhraa A. Ammar (Author), Abeer M. Abd Eltawab (Author), Nagy A. Sayed-Ahmed (Author)
• Formato: Livro
• Publicado em: The Korean Society of Nephrology, 2018-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background : In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In the present study, we explored the relation between obesity and...